Evidence map›Paper›PMID 40375697›Full record

ReviewCombinatorial chemistry & high throughput screening2026

Synergistic Interactions of Anthraquinones with Conventional Cancer Therapies.

Priyanka Sharma, Priya Ghanghas, Rituraj Niranjan, Sandeep Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Priyanka SharmaArmy Public School, Gaji Gadana, Beas, Punjab-144802, India.
Priya GhanghasParexel International India Pvt LTD, Mohali, Punjab-140308, India.
Rituraj NiranjanICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh-482003, India.
Sandeep KumarIndian Council of Medical Research, New Delhi-110029, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is a major public health concern, and conventional treatments like surgery, chemotherapy, and radiotherapy are associated with several disadvantages, including chemoresistance, toxicity, and economic burden to the family of cancer patients. Thus, discovery of novel agents of natural agents to reduce these side effects is crucial. A series of studies have shown anthraquinones as a promising adjuvant in enhancing the effectiveness of standard cancer therapies.

objectiveThis review explores the anticancer potential of anthraquinones and their role in enhancing standard chemotherapy. METHODOLOGY: Various freely available databases, including PubMed, Scopus, Google Scholar and Web of Science were searched for updated and relevant information on anthraquinones and their use as an adjuvant with standard chemotherapeutic agents.

resultsIn this article, we looked at the recent developments in the utilization of anthraquinones as adjuvants in chemotherapy. Further, we have elaborated the mechanism of action that anthraquinones target to chemosensitize the drug-resistant cancer cells.

conclusionThis review provides updated information on emerging role and their potential to be utilized as adjuvants in augmenting the efficacy of conventional cancer therapies.

Indexed as

AnthraquinonesAntineoplastic AgentsNeoplasmsAnimalsDrug Resistance, NeoplasmDrug SynergismHumansAnthraquinonesAntineoplastic AgentsadjuvantanthraquinoneCancerchemotherapynatural compounds

Identifiers

PMID40375697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.